According to the current guidelines, BRAF-wildtype patients with advanced melanoma should either receive a dual therapy with ipilimumab plus nivolumab or a monotherapy with nivolumab or pembrolizumab (PDL-1 inhibitor), on the basis of clinical discretion. This evidence concerns the gene BRAF and melanoma.